218 related articles for article (PubMed ID: 25908301)
41. Reciprocal actions of constrictor prostanoids and superoxide in chronic hypoxia-induced pulmonary hypertension: roles of EETs.
Kandhi S; Alruwaili N; Wolin MS; Sun D; Huang A
Pulm Circ; 2019; 9(4):2045894019895947. PubMed ID: 31908769
[TBL] [Abstract][Full Text] [Related]
42. Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: role of oxylipins and PPARγ.
Hanif A; Edin ML; Zeldin DC; Morisseau C; Nayeem MA
Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R676-R688. PubMed ID: 27488890
[TBL] [Abstract][Full Text] [Related]
43. Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.
Wang Q; Huo L; He J; Ding W; Su H; Tian D; Welch C; Hammock BD; Ai D; Zhu Y
Am J Physiol Heart Circ Physiol; 2015 Dec; 309(11):H1894-903. PubMed ID: 26453326
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of soluble epoxide hydrolase attenuates a high-fat diet-mediated renal injury by activating PAX2 and AMPK.
Luo Y; Wu MY; Deng BQ; Huang J; Hwang SH; Li MY; Zhou CY; Zhang QY; Yu HB; Zhao DK; Zhang G; Qin L; Peng A; Hammock BD; Liu JY
Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5154-5159. PubMed ID: 30804206
[TBL] [Abstract][Full Text] [Related]
45. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
Revermann M; Schloss M; Barbosa-Sicard E; Mieth A; Liebner S; Morisseau C; Geisslinger G; Schermuly RT; Fleming I; Hammock BD; Brandes RP
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):909-14. PubMed ID: 20224052
[TBL] [Abstract][Full Text] [Related]
46. Soluble epoxide hydrolase deficiency or inhibition enhances murine hypoxic pulmonary vasoconstriction after lipopolysaccharide challenge.
Wepler M; Beloiartsev A; Buswell MD; Panigrahy D; Malhotra R; Buys ES; Radermacher P; Ichinose F; Bloch DB; Zapol WM
Am J Physiol Lung Cell Mol Physiol; 2016 Dec; 311(6):L1213-L1221. PubMed ID: 27815261
[TBL] [Abstract][Full Text] [Related]
47. The soluble epoxide hydrolase determines cholesterol homeostasis by regulating AMPK and SREBP activity.
Mangels N; Awwad K; Wettenmann A; Dos Santos LR; Frömel T; Fleming I
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():30-9. PubMed ID: 27179554
[TBL] [Abstract][Full Text] [Related]
48. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling.
Cheng J; Ou JS; Singh H; Falck JR; Narsimhaswamy D; Pritchard KA; Schwartzman ML
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H1018-26. PubMed ID: 18156192
[TBL] [Abstract][Full Text] [Related]
49. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
50. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
[TBL] [Abstract][Full Text] [Related]
51. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension.
Singh H; Schwartzman ML
Pharmacol Rep; 2008; 60(1):29-37. PubMed ID: 18276983
[TBL] [Abstract][Full Text] [Related]
52. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
53. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
Sacerdoti D; Gatta A; McGiff JC
Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):51-71. PubMed ID: 14626496
[TBL] [Abstract][Full Text] [Related]
54. CCN1 acutely increases nitric oxide production via integrin αvβ3-Akt-S6K-phosphorylation of endothelial nitric oxide synthase at the serine 1177 signaling axis.
Hwang S; Lee HJ; Kim G; Won KJ; Park YS; Jo I
Free Radic Biol Med; 2015 Dec; 89():229-40. PubMed ID: 26393424
[TBL] [Abstract][Full Text] [Related]
55. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation.
Hutchens MP; Nakano T; Dunlap J; Traystman RJ; Hurn PD; Alkayed NJ
Resuscitation; 2008 Jan; 76(1):89-94. PubMed ID: 17728042
[TBL] [Abstract][Full Text] [Related]
56. A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow in the rat.
Iliff JJ; Close LN; Selden NR; Alkayed NJ
Exp Physiol; 2007 Jul; 92(4):653-8. PubMed ID: 17639071
[TBL] [Abstract][Full Text] [Related]
57. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
Imig JD
Cardiovasc Drug Rev; 2006; 24(2):169-88. PubMed ID: 16961727
[TBL] [Abstract][Full Text] [Related]
58. The role of the RhoA/Rho-kinase signaling pathway in renal vascular reactivity in endothelial nitric oxide synthase null mice.
Williams J; Bogwu J; Oyekan A
J Hypertens; 2006 Jul; 24(7):1429-36. PubMed ID: 16794494
[TBL] [Abstract][Full Text] [Related]
59. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.
Ai D; Fu Y; Guo D; Tanaka H; Wang N; Tang C; Hammock BD; Shyy JY; Zhu Y
Proc Natl Acad Sci U S A; 2007 May; 104(21):9018-23. PubMed ID: 17495027
[TBL] [Abstract][Full Text] [Related]
60. Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart.
Anwar-Mohamed A; El-Sherbeni AA; Kim SH; Althurwi HN; Zordoky BN; El-Kadi AO
Xenobiotica; 2012 Dec; 42(12):1235-47. PubMed ID: 22680237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
